CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD.
中化合成生技股份有限公司
Leave your email for change alerts (optional)
1964Founded
NT$769MPaid-in capital
2Plants
2Certifications
6Patents
NT$1–5BRevenue band
- Unified Business No.
- 03088704
- Industry
- Pharmaceuticals & Medicinal Chemicals (273)
- Main products
- Pharmaceuticals & medicinal chemicals (276)
- Location
- No. 1, Tung-Hsing St., Shulin Dist., New Taipei City 238010, Taiwan (R.O.C.)
New Taipei City (16,829) · Shulin Dist. (2,929) - Listing
- Listed (TWSE) (1,087) 1762
- Registration status
- Approved / Active
- Organisation type
- Company Limited by Shares
- Founded
- 1964-05-19
- Paid-in capital
- NT$ 769,180,000
- Representative
- Wang Hsieh-yi-chen
- Phone
- 86843318
- Website
- http://www.ccsb.com.tw
- Exporter
- Yes — registered with the Trade Administration
- Annual revenue band
- NT$1–5B
- Ownership
- Group subsidiary / corporate-held · CHINA CHEMICAL & PHARMACEUTICAL CO., LTD.、Tsai Tuan Fa Jen Wang Min Ning Hsien Sheng Chi Nien Chi Chin Huei
- North American market
- FDA drug establishment registration
- Representative tenure
- In office since 2021-07 (5 yrs); last handover 2021-07 (same surname)
- Growth & profitability
- Gross margin 40%, operating margin 17.2%, net margin 19.8% (2026-Q2 YTD)
- Compliance record
- Environmental penalties: 2 case(s) in 5 years, latest 2026-03-04, fines NT$ 72,000 (industrial waste)
Occupational safety penalties: 2 case(s) in 5 years, latest 2024-02-05, fines NT$ 60,000 (Art. 6) — matched by company name
Plants 2
- Shanjiagong Plant · No. 1, Dongxing St., Shulin Dist., New Taipei City In production
- Shulin Plant · No. 3, Dongxing St., Shulin Dist., New Taipei City In production
Certifications 2
Processes & materials 4
- Biotechnology (664) · Company nameSelf-reported
- EDM (216) · MachiningSelf-reported
- Cleanroom production (392) · Assembly & inspectionSelf-reported
- Milling (482) · MachiningSelf-reported
Patents 6
- 2026 Solid-phase disulfide cyclization preparation method for setmelanotide
- 2025 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzimidazole-5-carboxylic acid (2-ethyl
- 2024 Preparation method for trelagliptin and precursor thereof
North American market evidence 1
- FDA drug establishment registration 3002806677 12/31/2026
API MANUFACTURE
Recent changes 1
- PenaltiesEnvironmental penalties: latest case 2026-03-04; 2 case(s) in 5 years, fines NT$ 72,000
RSS feed · Recent changes at Taiwanese manufacturers →
Similar companies 10
- PROCHEM PHARMTECH CO., LTD. · Tainan City < NT$20M estimated
Shared: Biotechnology, Active pharmaceutical ingredient (API) manufacturing - PET PHARM BIOTECH CO., LTD. · New Taipei City Emerging stock (TPEx) NT$100–500M
Shared: Biotechnology, Cleanroom production, GMP - Taiwan Bio-Manufacturing Corporation · Hsinchu County NT$1–5B estimated
Shared: Active pharmaceutical ingredient (API) manufacturing - PLEXBIO CO., LTD. · Taipei City Emerging stock (TPEx) NT$100–500M
Shared: Biotechnology, FDA, GMP - PHYTOHEALTH CORPORATION · Taoyuan City Listed (TWSE) NT$100–500M
Shared: Biotechnology, FDA, GMP - ANDROS PHARMACEUTICALS CO., LTD. · Hsinchu County Emerging stock (TPEx) < NT$20M
Shared: FDA, GMP - SCINOPHARM TAIWAN LTD. · Tainan City Listed (TWSE) NT$1–5B
Shared: GMP, Active pharmaceutical ingredient (API) manufacturing - SAVIOR LIFETEC CORPORATION TAINAN BRANCH · Tainan City Listed (TPEx) NT$1–5B
Shared: Cleanroom production, GMP, Active pharmaceutical ingredient (API) manufacturing - TAIMED BIOLOGICS INC. · Hsinchu County Listed (TPEx) NT$0.5–1B
Shared: FDA, GMP - CHENG KUANG PHARMACEUTICAL CO., LTD. · Changhua County < NT$20M estimated
Shared: FDA, GMP